Algen Biotechnologies is a biotech company born from Jennifer Doudna’s lab at UC Berkeley, developing an AI-powered, single-cell CRISPR gene-modulation platform called AlgenCRISPR / AlgenBrain™. Their system seeks to reverse-engineer disease trajectories by modeling billions of dynamic RNA changes across cell states, enabling fine-tuned modulation of genes to isolate those that truly drive disease (rather than merely correlate). The company aims to industrialize this approach at human cellular scale to generate high-confidence causal biology, thereby improving the translational bridge from lab discoveries to therapeutic targets in complex disorders.